We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Janssen

News List

Johnson & Johnson pays $300m to develop cusatuzumab pharmatimes
December 07, 2018
Johnson & Johnson's Janssen has entered into an agreement potentially worth up to $1.6 billion to develop and market Argenx' cusatuzumab for a number of cancers, including haematological malignancies.
Ionis licenses another antisense GI drug to Janssen fiercebiotech
November 20, 2017
The candidate, IONIS-JBI2-2.5Rx, is orally delivered and acts on an undisclosed target to treat a gastrointestinal (GI) autoimmune disease.
Bavarian Nordic and Janssen to develop vaccines against HIV-1 and hepatitis B August 01, 2017
Danish biotechnology company Bavarian Nordic has entered an additional worldwide exclusive licence and collaboration agreement with Janssen Pharmaceuticals for the development of vaccine regimens against HIV-1 and hepatitis B.